Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI) is at the forefront of using data and artificial intelligence (AI) to create personalized cancer treatments, aiming for more effective therapies and better patient outcomes. The company's mission revolves around precision medicine in cancer diagnosis, leveraging several key resources:
- Database: A comprehensive database of clinically validated historical and outcome data from patient tumors.
- CLIA-Certified Lab: An in-house Clinical Laboratory Improvement Amendments (CLIA) certified lab.
- Smart Tumor Profiling: A patient-derived tumor profiling platform that offers intelligent insights.
- Bioinformatics AI Platform: An advanced AI platform for in-house bioinformatics.
- Innovative Tumor Growth: Techniques for growing tumors in the lab to rapidly develop patient-specific treatment options.
- FDA-Approved System: The FDA-approved STREAMWAY System for automated medical fluid waste management.
Predictive Oncology's business is structured across three main segments:
- Pittsburgh Segment: Focuses on AI applications using a proprietary biobank with over 150,000 tumor samples and creates 3D culture models for drug development.
- Birmingham Segment: Provides contract research services targeting solubility improvements, stability studies, and protein production.
- Eagan Segment: Produces the FDA-cleared STREAMWAY System for medical fluid disposal, driving the majority of the company's revenue.
Recent achievements highlight the company's collaborative efforts with pharmaceutical, diagnostic, and biotech industries:
- Hosted an investor call and webcast on November 14th, providing insights into future strategies and financial performance.
- Presented a study in collaboration with UPMC Magee-Womens Hospital, utilizing AI to predict ovarian cancer survival outcomes better than clinical data alone.
- Announced a partnership with FluGen to develop a stable intranasal flu vaccine, leveraging Predictive Oncology’s biologics capabilities.
- Unveiled a proprietary 3D cell culture model to enhance cancer drug discovery.
- Introduced a new platform for functional and stable G-Protein Coupled Receptors (GPCRs), targeting advancements in cancer therapeutics.
Predictive Oncology's AI platform, PEDAL, has been validated to predict tumor sample responses to drug compounds with 92% accuracy. This platform, combined with the company's biobank of over 150,000 tumor samples and CLIA lab facilities, positions Predictive Oncology as a leader in AI-driven drug discovery and development.
Predictive Oncology Inc. (NASDAQ: POAI) has announced a registered direct offering, issuing approximately 4.22 million shares at $1.75 per share, resulting in gross proceeds of about $7.4 million. The company will also issue warrants for up to 2.11 million shares with an exercise price of $2.00 per share. The offering is set to close on or around February 16, 2021. Funds will be directed towards working capital. The shares are offered under a previously filed registration statement with the SEC.
Predictive Oncology (NASDAQ: POAI) announced the initiation of an in-house drug repurposing project targeting ovarian cancer using its AI-driven platform, PeDAL™. This project aims to quickly and affordably profile existing drugs across various patient cell lines, generating vital data to enhance the PeDAL approach and enrich the company's Intellectual Property. CEO Dr. Carl Schwartz emphasized the project’s potential to add significant value through proof data, supporting commercial negotiations with pharmaceutical firms and positioning the company as a leader in AI-driven drug discovery.
Predictive Oncology (NASDAQ: POAI) announced a new contract with a large pharmaceutical company through its subsidiary Soluble Biotech. This collaboration aims to enhance the solubility and stability of a protein therapeutic for future clinical use. Dr. Larry DeLucas, President of Soluble Biotech, indicated this opportunity could pave the way for a long-term strategic partnership, supporting additional therapeutics under development by the pharmaceutical company. Predictive Oncology utilizes AI in personalized medicine and operates across several segments.
Predictive Oncology (NASDAQ: POAI) announced the closing of a registered direct offering of 3,414,970 shares at $1.20 each, generating approximately $4.1 million in gross proceeds. Concurrently, the company issued unregistered warrants for 1,707,485 additional shares at an exercise price of $1.37. The funds from this offering will be used for working capital. H.C. Wainwright & Co. acted as the exclusive placement agent. The warrants and underlying shares have not been registered and may not be sold in the U.S. without an effective registration statement.
Predictive Oncology (NASDAQ: POAI) announced a registered direct offering of approximately 3,414,970 shares of common stock at $1.20 per share, generating approximately $4.1 million in gross proceeds. The offering includes unregistered warrants for up to 1,707,485 additional shares at an exercise price of $1.37, expiring in five and a half years. The funds will be used for working capital, with the offering's closing expected around January 26, 2021. The transaction is facilitated by H.C. Wainwright & Co.
Predictive Oncology Inc. (NASDAQ: POAI) announced the closing of a registered direct offering of 2,200,000 shares at $1.00 per share, generating $2.2 million in gross proceeds. This offering was executed under Nasdaq rules, with unregistered warrants for 1,100,000 shares also issued at the same price. The company plans to utilize the net proceeds for working capital. H.C. Wainwright & Co. served as the exclusive placement agent. The shares were registered under a previous SEC filing, while the warrants remain unregistered under the Securities Act.
Predictive Oncology (NASDAQ: POAI) has announced a registered direct offering, issuing approximately 2.2 million shares at $1.00 each, expected to generate gross proceeds of $2.2 million. The offering includes unregistered warrants for an additional 1.1 million shares with the same exercise price. Closing is anticipated around January 21, 2021. Funds from this offering will primarily be used for working capital. H.C. Wainwright & Co. serves as the exclusive placement agent for the offering.
Predictive Oncology (NASDAQ: POAI) announced its subsidiary, TumorGenesis, Inc., has secured repeat media orders from two leading research centers in New York and Boston for culturing ovarian cancer cells. Additionally, a private company placed an order for ovarian cancer research. The company's CEO emphasized the significance of developing a 'living library' of cancer cells for drug discovery, stating it could lead to effective treatments for ovarian cancer. The 3D cancer cell culture media market is projected to grow significantly, reaching $3.2 billion by 2027.
Predictive Oncology (NASDAQ: POAI) has completed a registered direct offering of 3,650,840 shares at $0.842 each, raising $3.074 million before expenses. In a related private placement, it issued warrants for 1,825,420 shares at an exercise price of $0.80 per share. The funds will be used for working capital. The offering was managed by H.C. Wainwright & Co., and the shares were offered under an effective shelf registration statement. This transaction highlights the company's ongoing efforts in applying AI for personalized medicine and drug discovery.
Predictive Oncology (NASDAQ: POAI) announced definitive agreements for the sale of 3,650,840 shares at $0.842 each, totaling approximately $3.0 million in gross proceeds through a registered direct offering. The company will also issue warrants for 1,825,420 shares with an exercise price of $0.80, expiring in five and a half years. The offering is expected to close around January 12, 2021. Proceeds are intended for working capital purposes. H.C. Wainwright & Co. serves as the exclusive placement agent for this transaction.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
What does Predictive Oncology Inc. specialize in?
What are the key segments of Predictive Oncology’s business?
What recent collaborations has Predictive Oncology announced?
How accurate is Predictive Oncology’s AI platform PEDAL?
What is the significance of Predictive Oncology’s 3D cell culture model?
How does Predictive Oncology’s STREAMWAY System benefit the healthcare industry?
What are GPCRs and why are they important in cancer treatment?
What is Predictive Oncology’s biobank?
Where is Predictive Oncology headquartered?
Who can I contact for investor relations at Predictive Oncology?
